Stop REMS Abuse - Anti-competitive practices are costing patients billions - you can help!

AAM Applauds House Passage of FDA User Fee Reauthorization

Calls on Senate to Send Measure to President Trump’s Desk

WASHINGTON, DC (July 12, 2017) – The Association for Accessible Medicines (AAM) today applauds the passage of H.R. 2430, the FDA Reauthorization Act of 2017 through the House of Representatives and urges the Senate to take action on the legislation immediately to ensure the timely reauthorization of the Generic Drug User Fee Amendments (GDUFA II) and the Biosimilar User Fee Act (BsUFA II).

“The U.S. House of Representatives has shown important leadership toward ensuring more safe, effective and affordable generic and biosimilar medicines are available to America’s patients in a timely manner,” said Chester “Chip” Davis, Jr., President and CEO of AAM. “We urge the Senate to act and for Congress to send this measure to President Trump’s desk so we can continue to make progress toward containing the cost of prescription drugs in the U.S.”

Read the Letter